92 related articles for article (PubMed ID: 3768871)
41. Toxicology and Carcinogenesis Studies of Mercuric Chloride (CAS No. 7487-94-7) in F344 Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Feb; 408():1-260. PubMed ID: 12621522
[TBL] [Abstract][Full Text] [Related]
42. Platinum concentrations in human autopsy tumor samples.
Stewart DJ; Mikhael NZ; Nair RC; Kacew S; Montpetit V; Nanji A; Maroun JA; Howard K
Am J Clin Oncol; 1988 Apr; 11(2):152-8. PubMed ID: 3358362
[TBL] [Abstract][Full Text] [Related]
43. Concentration of vinblastine in human intracerebral tumor and other tissues.
Stewart DJ; Lu K; Benjamin RS; Leavens ME; Luna M; Yap HY; Loo TL
J Neurooncol; 1983; 1(2):139-44. PubMed ID: 6678966
[TBL] [Abstract][Full Text] [Related]
44. Detection and quantification of mitoxantrone in human organs. A case report.
Roboz J; Paciucci PA; Silides D; Greaves J; Holland JF
Cancer Chemother Pharmacol; 1984; 13(1):67-8. PubMed ID: 6375887
[No Abstract] [Full Text] [Related]
45. Poly(I).poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study.
Eichler HG; Mader R; Blöchl-Daum B; Steger G; Rainer H
Cancer Chemother Pharmacol; 1987; 20(1):81-2. PubMed ID: 3621457
[TBL] [Abstract][Full Text] [Related]
46. Tumors of the Brain Disclosed by Autopsy.
Gill HD
J Comp Med Vet Arch; 1895 Aug; 16(8):502-503. PubMed ID: 36391670
[No Abstract] [Full Text] [Related]
47. Thymus Subset Alterations Accompanying Concomitant Tumor Immunity Mimics Phenotypic Patterns of Cytotoxic Drug Doxorubicin.
Zaleskis G; Characiejus D; Jursenaite J; Zibutyte L; Kriauciunaite K; Vanagaite-Zickiene M; Darinskas A; Jonusis M; Pasukoniene V
In Vivo; 2022; 36(3):1106-1113. PubMed ID: 35478153
[TBL] [Abstract][Full Text] [Related]
48. Chemobrain: mitoxantrone-induced oxidative stress, apoptotic and autophagic neuronal death in adult CD-1 mice.
Dias-Carvalho A; Ferreira M; Reis-Mendes A; Ferreira R; Bastos ML; Fernandes E; Sá SI; Capela JP; Carvalho F; Costa VM
Arch Toxicol; 2022 Jun; 96(6):1767-1782. PubMed ID: 35306571
[TBL] [Abstract][Full Text] [Related]
49. Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.
Costa VM; Capela JP; Sousa JR; Eleutério RP; Rodrigues PRS; Dores-Sousa JL; Carvalho RA; Lourdes Bastos M; Duarte JA; Remião F; Almeida MG; Varner KJ; Carvalho F
Arch Toxicol; 2020 Dec; 94(12):4067-4084. PubMed ID: 32894303
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.
Shaaban S; Negm A; Ibrahim EE; Elrazak AA
Oncol Rev; 2014 Mar; 8(1):246. PubMed ID: 25992234
[TBL] [Abstract][Full Text] [Related]
51. Current and future treatment approaches for neuromyelitis optica.
Collongues N; de Seze J
Ther Adv Neurol Disord; 2011 Mar; 4(2):111-21. PubMed ID: 21694808
[TBL] [Abstract][Full Text] [Related]
52. Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
Boiardi A; Eoli M; Salmaggi A; Lamperti E; Botturi A; Broggi G; Bissola L; Finocchiaro G; Silvani A
J Neurooncol; 2005 Nov; 75(2):215-20. PubMed ID: 16283445
[TBL] [Abstract][Full Text] [Related]
53. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
Boiardi A; Bartolomei M; Silvani A; Eoli M; Salmaggi A; Lamperti E; Milanesi I; Botturi A; Rocca P; Bodei L; Broggi G; Paganelli G
J Neurooncol; 2005 Apr; 72(2):125-31. PubMed ID: 15925992
[TBL] [Abstract][Full Text] [Related]
54. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.
Boiardi A; Eoli M; Salmaggi A; Zappacosta B; Fariselli L; Milanesi I; Broggi G; Silvani A
J Neurooncol; 2001 Aug; 54(1):39-47. PubMed ID: 11763421
[TBL] [Abstract][Full Text] [Related]
56. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB; Nahata MC
Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
[TBL] [Abstract][Full Text] [Related]
57. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.
Wiseman LR; Spencer CM
Drugs Aging; 1997 Jun; 10(6):473-85. PubMed ID: 9205852
[TBL] [Abstract][Full Text] [Related]
58. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
Rentsch KM; Horber DH; Schwendener RA; Wunderli-Allenspach H; Hänseler E
Br J Cancer; 1997; 75(7):986-92. PubMed ID: 9083333
[TBL] [Abstract][Full Text] [Related]
59. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.
Dunn CJ; Goa KL
Drugs Aging; 1996 Aug; 9(2):122-47. PubMed ID: 8820798
[TBL] [Abstract][Full Text] [Related]
60. Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.
Boiardi A; Salmaggi A; Pozzi A; Broggi G; Silvani A
J Neurooncol; 1996 Feb; 27(2):157-62. PubMed ID: 8699238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
